Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.
about
Innate Immune Memory: The Latest Frontier of AdjuvanticityThe non-specific effects of vaccines and other childhood interventions: the contribution of INDEPTH Health and Demographic Surveillance SystemsRevaccination with Live Attenuated Vaccines Confer Additional Beneficial Nonspecific Effects on Overall Survival: A ReviewTechnological Microbiology: Development and ApplicationsCytomegalovirus infection enhances the immune response to influenza.Effect of early measles vaccine on pneumococcal colonization: A randomized trial from Guinea-Bissau.Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau.Measles vaccination in the presence or absence of maternal measles antibody: impact on child survival.Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges.Measles-mumps-rubella vaccination and respiratory syncytial virus-associated hospital contactReady to benefit from training: heterologous effects of early life immunization.Vaccination and heterologous immunity: educating the immune systemGender-specific mortality in DTP-IPV- and MMR±MenC-eligible age groups to determine possible sex-differential effects of vaccination: an observational studyThe effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study.Oral Polio Vaccination and Hospital Admissions With Non-Polio Infections in Denmark: Nationwide Retrospective Cohort StudyHarnessing the beneficial heterologous effects of vaccination.Simultaneous vaccination with MMR and DTaP-IPV-Hib and rate of hospital admissions with any infections: A nationwide register based cohort study.Does oral polio vaccine have non-specific effects on all-cause mortality? Natural experiments within a randomised controlled trial of early measles vaccine.BCG vaccination at birth and early childhood hospitalisation: a randomised clinical multicentre trial.Is early measles vaccination better than later measles vaccination?Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands.Making a Case for Pediatric Antimicrobial Stewardship Programs.Nonspecific effect of BCG vaccination at birth on early childhood infections: a randomized, clinical multicenter trial.Immunization enhances the natural antibody repertoire.Timing of routine infant vaccinations and risk of food allergy and eczema at one year of age.Risk of non-targeted infectious disease hospitalizations among U.S. children following inactivated and live vaccines, 2005-2014.Text message reminders for timely routine MMR vaccination: A randomized controlled trial.Specialized survivor clinic attendance is associated with decreased rates of emergency department visits in adult survivors of childhood cancer.Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.Does routine symptom screening with ESAS decrease ED visits in breast cancer patients undergoing adjuvant chemotherapy?Randomized Trial of 2 Versus 1 Dose of Measles Vaccine: Effect on Hospital Admission of Children After 9 Months of Age.Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971-2010.Beneficial Nonspecific Effects of Oral Polio Vaccine (OPV): Implications for the Cessation of OPV?A marginal structural model for recurrent events in the presence of time-dependent confounding: non-specific effects of vaccines on child hospitalisations.Infectious Agents as Stimuli of Trained Innate Immunity.Uptake of Cancer Screening Tests Among Recipients of Solid Organ Transplantation.National Immunization Campaigns with Oral Polio Vaccine Reduce All-Cause Mortality: A Natural Experiment within Seven Randomized Trials.Association Between Estimated Cumulative Vaccine Antigen Exposure Through the First 23 Months of Life and Non-Vaccine-Targeted Infections From 24 Through 47 Months of Age.Evidence of Increase in Mortality After the Introduction of Diphtheria-Tetanus-Pertussis Vaccine to Children Aged 6-35 Months in Guinea-Bissau: A Time for Reflection?Human Vaccines & Immunotherapeutics: News.
P2860
Q26783968-4D02D586-683F-46E5-9085-3AB765761C7BQ27027641-D2302FB5-476D-4CEB-A599-06F9CAF40047Q28596501-1DEC97A9-7813-49E7-8D8B-3EC4527B5FD9Q30250972-01593124-155B-440D-BFBC-1B87E46AE50BQ30300254-CBC72B37-CC64-4BAB-B89A-C9486C8626F2Q33699031-CDFF0EE1-C308-4B50-961F-AAD8DD968A54Q33717518-9F75E0B4-CE22-40E7-8C62-9DA0292571E3Q33953925-21EE575E-A643-4FE4-B8CD-34F03C9E0D5EQ34439339-08DDDA24-F058-4513-A3C2-712073293A32Q34450699-CB64B6A6-F9E3-4766-98C8-5AC3EACE01CFQ35152743-BF747504-BA36-498F-BF59-4185D43999E4Q35152750-688A9AF3-53BD-47C6-B595-BF723159FB1BQ35238177-C2D1F816-0EE9-40B6-8AF9-92100A21414CQ36398934-AC547D58-4713-48A5-88DA-F850CE4E2149Q36573881-83C76760-EC3C-45F2-8B80-62266BF7E2D4Q37061098-C30F5A7C-5CA2-46A9-AEB6-D04625CE3693Q37481313-F55ECC1C-98E4-4536-87AD-2AFD4A141A7EQ37576859-64BF2849-6F93-4C6C-B87C-D54A100F41D6Q37683603-25495331-47FD-4CAF-A8A6-FA8EAB30692DQ38312176-3C8D7881-0C92-4675-9C42-F285974661FDQ38601756-0D672274-A77D-4BDC-A85B-B1A7F03D87EBQ38644813-14EBE513-BAC1-4F31-9D54-34277A17E05FQ39590232-E8502B7B-86C6-4193-8E92-3C6941BEE2C3Q40050168-FEB700CA-1BEB-43F7-82E5-31066AE9C3EEQ40168170-751A90D5-C581-4C88-8709-1431C64B716BQ40221930-C8EA527F-A851-467B-BE78-0422009B1BDDQ40318619-D703D407-E194-4082-8F26-DBFB93CD614BQ40500988-1B32DB27-FB31-4FF0-8F96-10B3F288EC86Q40779986-CE942E23-22F4-460D-AF7C-F67CC3A5524BQ41357319-47D137A9-693A-4AC6-AB7F-906BC11DB4D9Q42695860-2DE16A4B-8025-4A07-BDF7-F7AB6BE79E85Q46489440-AE3286B0-D146-4874-B24C-40A1368C7927Q46690442-03C72EFE-94D9-4A8B-8E88-36201A2B6316Q47386936-209396E0-3080-4F05-AF6B-6FE576BB52C0Q48104891-1FA396FF-B42F-4AE8-AD19-25F4F3EA4BF0Q48172285-D5C47685-9717-47A5-8712-B09380B145F4Q49832015-66DB43D0-794C-483B-8E21-E02137874CDBQ52365716-EEC6B1E0-C677-4C86-86D2-4C17D99A0AE7Q53278311-7B8CA0A0-8415-4DA7-BF3B-47349F51787AQ54503272-6A88894A-846A-43B3-95C4-CBCDD6B0A4C9
P2860
Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Live vaccine against measles, ...... ns for nontargeted infections.
@ast
Live vaccine against measles, ...... ns for nontargeted infections.
@en
Live vaccine against measles, ...... ns for nontargeted infections.
@nl
type
label
Live vaccine against measles, ...... ns for nontargeted infections.
@ast
Live vaccine against measles, ...... ns for nontargeted infections.
@en
Live vaccine against measles, ...... ns for nontargeted infections.
@nl
prefLabel
Live vaccine against measles, ...... ns for nontargeted infections.
@ast
Live vaccine against measles, ...... ns for nontargeted infections.
@en
Live vaccine against measles, ...... ns for nontargeted infections.
@nl
P2093
P50
P356
P1476
Live vaccine against measles, ...... ns for nontargeted infections.
@en
P2093
Anja Poulsen
Henrik Ravn
Tyra G Krause
P304
P356
10.1001/JAMA.2014.470
P407
P577
2014-02-01T00:00:00Z